复方牛胎肝提取物联合复方鳖甲软肝片治疗乙肝肝硬化临床分析

目的:观察复方牛胎肝提取物联合复方鳖甲软肝片治疗乙肝肝硬化的临床疗效。方法:64例乙肝肝硬化患者随机分为复方牛胎肝提取物联合复方鳖甲软肝片治疗组及对照组。每个3月查肝功1次,肝纤维化等指标,观察其临床表现。结果:6个月后,治疗组及对照组肝功明显恢复,2组比较差异显著,有统计学意义(P<0.05)。治疗组和对照组在治疗后ALT、TBIL、ALB较治疗前明显改善(P<0.05);治疗组肝组织纤维化程度比对照组改善更明显。治疗组患者HA、IV-C、LN及PCIII分别降低了55.58%、44.76%、36.65%、54.89%,对照组上述指标分别降低了33.55%、22.80%、14.77%和13.56%,2组间有显著性差异(P<0.05)。结论:复方牛胎肝提取物联合复方鳖甲软肝片治疗乙肝肝硬化疗效较为理想。

Clinical study of Fufang Biejia Ruangan Tablet common Compound Embryonic Bovine Liver Extract Tablets on chronichepatitis B patients complicated with hepatocirrhosis

Objective: To explore the mechanism of Fufang Biejia Ruangan Tablet common Compound Embryonic Bovine Liver Extract Tablets treating hepatocirrhosis. Methods: 64 cases of hepatocirrhosis were randomly divided into Fufang Biejia Ruangan Tablet common Compound Embryonic Bovine Liver Extract Tablets group and Fufang Biejia Ruangan Tablet group. Check hepatic functional and liver fibrosis every three month and observe its clinical changes. Results: After six months,hepatitis functional were significantly improved in treatment group and control group . There was statistically significant differences between two groups(P<0.05). TBIL、ALB and ALT of treatment group were improved After treatmen(tP<0.05)compared with before treatment. Liver tissue fibrosis of treatment group was more obvious improvement. HA、IV-C、PCIII and LN of treatment groups of patients and decreased the 55.58% 、 44.76%、36.65%、54.89%. These projects were decreased 33.55%、22.80%、14.77%、13.56. Here was statistically significant differences between two groups(P<0.05). Conclusion: Therapy of Fufang Biejia Ruangan Tablet common Compound Embryonic Bovine Liver Extract Tablets on chronic hepatitis B patients complicated with hepatocirrhosis may be an ideal effect.